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a  b  s  t  r  a  c  t
Chrysin  (5,7-dihydroxyﬂavone)  is a ﬂavonoid,  natural  component  of  traditional  medici-
nal herbs,  present  in  honey,  propolis  and  many  plant  extracts.  The  objective  of  this  study
was  to investigate  the  hypolipidemic  properties  of chrysin  on  Triton  WR-1339-induced
hyperlipidemia  in female  C57BL/6  mice.  Triton  WR-1339  was  administered  intraperi-
toneally  (400  mg/kg)  to  overnight-fasted  mice  to develop  acute  hyperlipidemia.  Chrysin
was  administered  orally  (10  mg/kg)  30  min  before  Triton  WR-1339.  At  24  h after  Triton  WR-
1339 injection,  blood  samples  were  collected  to  measure  plasma  lipid levels.  The  hepatic
thiobarbituric  acid  reactive  substances  (TBARS),  carbonyl  content,  non-protein  sulfhydryl
(NPSH)  and ascorbic  acid (AA)  levels,  as  well  as  catalase  (CAT)  and  superoxide  dismutase
(SOD) activity  were  recorded.  Chrysin  administration  signiﬁcantly  decreased  total  choles-
terol levels.  In  addition,  it partially  decreased  non-high  density  lipoprotein-cholesterol  and
triglycerides  levels  in  plasma  of  hyperlipidaemic  mice.  In addition  chrysin  administration
prevented  the  increase  on  TBARS  levels  and  prevented  the  decrease  in SOD activity  induced
by Triton  WR-1339.  These  ﬁndings  indicated  that chrysin  was  able  to decrease  plasma
lipids  concentration  and  that  its antioxidant  properties  was,  at least  in  part,  involved  in the
hypolipidaemic  action  of chrysin.
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1. Introduction
The liver is a key organ for lipid metabolism since
hepatic cholesterol uptake from serum, coupled with intra-
cellular  processing and biliary excretion is an important
feature in removal of excess cholesterol from the body,
beyond synthesis and metabolism of cholesterol, bile acids
and  phospholipids [1]. Cholesterol is an essential con-
stituent of most biological membranes, besides acting as
a  precursor for the synthesis of bile acids, hormones and
vitamins [2].
∗ Corresponding author. Tel.: +55 55 3433 1669.
E-mail addresses: marinaprigol@gmail.com,
marinaprigol@yahoo.com.br (M.  Prigol).
http://dx.doi.org/10.1016/j.toxrep.2014.02.003
2214-7500/© 2014 The Authors. Published by Elsevier Ireland Ltd. Th
(http://creativecommons.org/licenses/by-nc-nd/3.0/).ished  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
D  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
High circulating cholesterol is associated with hyper-
cholesterolemia, atherosclerosis, stroke [3] and increases
the  risk of cardiovascular diseases, fatty liver, and car-
cinogenesis [4]. Clinically, statins effectively lower plasma
cholesterol by inhibiting HMG-CoA reductase activity [5].
Simvastatin is one of the lipid-lowering drugs used to
inhibit  this enzyme [6].
Taking into account that the liver plays a central role
in  the maintenance of systemic lipid homeostasis, it can
be  susceptible to damage by reactive oxygen species
(ROS) [47]. Studies have demonstrated that hyperlipidemia
reduces the hepatic antioxidant defense system [7,8].
Humans are constantly exposed to free radicals cre-
ated by several factors [9]. The excessive free radical
generation may  induce a number of alterations of cell con-
stituents,  including inactivation of enzymes, generation of
is is an open access article under the CC BY-NC-ND license
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eactive nitrogen species, damage of nucleic acid bases
nd  proteins, and peroxidation of membrane lipids [10].
ntioxidants defense systems co-evolved along with aero-
ic  metabolism to counteract oxidative damage from free
adicals.  Antioxidant is further supported with antioxidant
nzymes, superoxide dismutase (SOD), catalase (CAT), glu-
athione  reductase (GR) and glutathione peroxidase (GPx),
s  well as by naturally occurring antioxidants like, vita-
in  E, -carotene, ascorbate, urate, and many others [48]
hat  exert synergistic actions in removing free radicals [9].
umar  et al. [8] demonstrated that there was a signiﬁ-
ant increase in hepatic markers of oxidative damage, such
s  lipid peroxidation, accompanied by deteriorating enzy-
atic  and non enzymatic antioxidant status in rats fed a
igh  cholesterol diet for 30 days.
The nonionic detergent, Triton WR1339 (Tyloxapol or an
xyethylated tertiary octyl phenol formaldehyde polymer),
s  used by several studies to induce hypercholesterolemia
n animals [11,12]. Its function is to inhibit the activity of
he  enzyme lipoprotein lipase, resulting in the accumula-
ion of triglycerides and VLDL in plasma, beyond causes a
igniﬁcant  increase in hepatic cholesterol biosynthesis by
timulating the activity of the enzyme HMG-CoA reductase
13].
Chrysin (5,7-dihydroxyﬂavone) is a natural ﬂavonoid
hich is contained in many plant extracts, ﬂowers such
s  the blue passion ﬂower (Passiﬂora caerulea), honey
nd propolis [14], beyond is the major component of
ome  traditional medicinal herbs [15]. It possesses anti-
nﬂammatory and antioxidant properties and it is used as
 dietary supplement [16]. Most studies show the effects
f  chrysin in the regulation of the reproductive system and
ormones,  it was effective in antagonizing the enzyme aro-
atase,  thus preventing the conversion of testosterone to
stradiol,  a desirable effect for body builders to increase
heir muscle mass [17]. Chrysin has also been shown
o  inhibit tumour angiogenesis in vivo [18], it presents
nti-viral [19], and anxiolytic [20] anti-allergic [21] and
nti-estrogenic [22] activity. It has remarkably beneﬁcial
harmacological effects [23], the most important and most
eported  is its anti-oxidant capacity [24]. Chrysin also alter
yperlipidemia induced by other stimulants. Pushpavalli
t  al. [15] demonstrated that chrysin was able to decrease
he  levels of plasma lipids caused by d-galactosamine in
ats.
Considering that liver is the major organ responsible for
holesterol transport, metabolism and excretion it is rea-
onable  to study hepatic lipaemic-oxidative disturbances
n hypercholesterolemia [25]. The aim of this study was
o  investigate hypolipidemic properties of chrysin and its
ntioxidant effect in a model of hyperlipidemia induced by
riton  WR-1339 in female C57BL/6 mice.
. Materials and methods
.1.  ChemicalsChrysin, simvastatin and Triton WR-1339 (Tyloxapol)
Fig. 1) were purchased from Sigma–Aldrich (St. Louis, MO,
SA).  Simvastatin and Triton WR-1339 were dissolved in
aline  solution (pH 7.4) and chrysin was dissolved in PEGports 1 (2014) 200–208 201
(Polyetylenoglicol 20%) and saline solution (pH 7.4). The
doses  of the compounds used in this study are: Triton
WR-1339 (400 mg/kg, 2.5 ml/kg, i.p.) based on [7]; Chrysin
(10  mg/kg; 10 ml/kg, p.o.), based on a pilot study previ-
ously conducted by our research group in C57BL/6 mice,
that  demonstrated that the compound is safe in this dose;
and  Simvastatin (10 mg/kg body W.T.) was used as the ref-
erence  standard drug for evaluating the antihyperlipidemic
activity, based on Sikarwar and Patil [26], since it is effec-
tive  in reduces plasma cholesterol by inhibiting HMG-CoA
reductase activity and reduces the risk of coronary events
during treatment. All other chemicals were obtained from
analytical grade or from standard commercial suppliers.
2.2.  Animals
Adult female C57BL/6 mice (16–25 g) were used. The
animals were kept on a 12 h light/dark cycle, at room tem-
perature (22 ± 2 ◦C), with free access to food and water. All
experiments were approved by Ethics Committee on Ani-
mal  Use (CEUA) of Universidade Federal do Pampa (number
011/2013). All efforts were made to minimize suffering
and to reduce the number of animals used in the exper-
iments. Mice were fasted for 12 h and then divided into
six  groups. Group 1 – control (n = 7): mice received canola
oil  (10 ml/kg, p.o.) 30 min  before saline (2.5 ml/kg, i.p.).
Group 2 – chrysin (n = 6): mice received chrysin (10 mg/kg;
10  ml/kg, p.o.) 30 min  before saline (2.5 ml/kg, i.p.). Group 3
–  simvastatin (n = 6): mice received simvastatin (10 mg/kg;
10  ml/kg, p.o.) 30 min  before saline (2.5 ml/kg, i.p.). Group
4  – Triton WR-1339 (n = 7): mice received canola oil
(10  ml/kg, p.o.) 30 min  before Triton WR-1339 (400 mg/kg,
2.5  ml/kg, i.p.); Group 5 – chrysin + Triton WR-1339 (n = 5):
mice  received (10 mg/kg; 10 ml/kg, p.o.) 30 min  before
Triton WR-1339 (400 mg/kg, 2.5 ml/kg, i.p.). Group 6 –
simvastatin + Triton WR-1339 (n = 6): mice received sim-
vastatin (10 mg/kg; 10 ml/kg, p.o.) 30 min  before Triton
WR-1339 (400 mg/kg, 2.5 ml/kg, i.p.). All animals remained
in  a fasted state for the duration of the experiment (36 h)
[25].
2.3.  Experiments
At  24 h after the Triton WR-1339 injection, blood sam-
ples  were collected directly from the ventricle of the
heart in anaesthetized animals, using heparin as the anti-
coagulant, and plasma was separated by centrifugation
(2400 × g) for 15 min. Subsequently mice were euthanized
by decapitation. The livers were quickly removed and
homogenized in 50 mM Tris–HCl, pH 7.4 (1/10, w/v). The
homogenate was centrifuged at 2400 × g at 4 ◦C for 15 min
and  a low-speed supernatant fraction (S1) was  used for
assays.
2.4.  Plasma Lipid levels
Plasma  total cholesterol, high-density lipoprotein
(HDL)-cholesterol and triglycerides were determined by
enzymatic  colorimetric methods using commercial kits
(Labtest  Diagnostica, MG,  Brazil). Non-HDL values were
obtained by the difference between total cholesterol and
202 M.S. Zarzecki et al. / Toxicology Reports 1 (2014) 200–208
hrysin a
the  S1 and the substrate (H2O2) to a concentration ofFig. 1. Structure of c
HDL-cholesterol levels. Plasma lipid levels were expressed
as  mg/dl.
2.5. Oxidative stress markers
Thiobarbituric  acid reactive species (TBARS), a measure
of  lipid peroxidation, were determined using an aliquot
(200  l) of S1, 500 l thiobarbituric acid (0.8%), 200 l
sodium dodecil sulfate (SDS, 8.1%) and 500 l acetic acid,
the  mixture was incubated at 95 ◦C for 2 h. TBARS (thiobar-
bituric acid reactive species) were determined as described
by  Ohkawa et al. [27]. TBARS levels were expressed as nmol
MDA/mg  protein.
2.5.1.  Protein carbonyl content
Carbonyl content was determined by a method based
on  the reaction of protein carbonyls with dinitrophenyl-
hydrazine forming dinitrophenylhydrazone, a yellow
compound [28]. Brieﬂy, homogenized the liver tissue were
diluted  1:10 (v/v) and an aliquot of 1 ml  was added to the
reaction  mixture containing 200 l of 10 mM dinitrophenyl
hydrazine (prepared in 2 M HCl). The samples were kept in
the  dark for 1 h and the tubes were shaken with a Vor-
tex mixer each 15 min. After that, 500 l of denaturation
buffer, 1.5 ml  of ethanol and 1.5 ml  of hexane were added
to  each tube. The tubes were shaken with a Vortex mixer
for  40 s and centrifuged for 15 min  to 3000 rpm. The super-
natants  obtained were discarded. The pellets were washed
two  times with 1 ml  ethanol: ethyl acetate (1:1, v/v) andnd Triton WR-1339.
ressuspended in 1 ml  of denaturation buffer. The sample
tubes were shaken with a Vortex mixer for 5 min. These
samples were used to measure absorbance at 370 nm (UV).
Results  were reported as carbonyl content (nmol/mg pro-
tein).
2.6.  Enzymatic antioxidant defenses
SOD activity was assayed spectrophotometrically as
described by Misra and Fridovich [29]. This method is
based  on the capacity of SOD to inhibit autooxidation
of epinephrine to adrenochrome. Enzymatic reaction was
initiated  by adding an aliquot (20–60 l) of the S1 and
the substrate (epinephrine) to a concentration of 60 mM
in  a medium containing 50 mM glycine buffer, pH 10.3.
The  colour reaction was  measured at 480 nm.  One unit of
enzyme  was deﬁned as the amount of enzyme required
to  inhibit the rate of epinephrine autooxidation by 50% at
26 ◦C. The enzymatic activity was expressed SOD activity
as  units (U)/mg protein.
CAT  activity was assayed spectrophotometrically by
the  method of Aebi [30], which involves monitoring the
disappearance of H2O2 in the S1 at 240 nm.  Enzymatic
reaction was  initiated by adding an aliquot of 20 l of0.3  mM in a medium containing 50 mM phosphate buffer,
pH  7.0. The enzymatic activity was expressed in Units (one
Unit  decomposes 1 mole of H2O2 per min  at pH 7 at
25 ◦C).
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.7. Non enzymatic antioxidant defenses
.7.1. Non-protein sulfhydryl (NPSH) content
To determine NPSH, S1 was mixed (1:2) with 10%
richloroacetic acid. After the centrifugation, the protein
ellet was discarded and free SH groups were deter-
ined in the clear supernatant. An aliquot of supernatant
as added in 1 M potassium phosphate buffer pH 7.4 and
0  mM DTNB [31]. The colour reaction was measured at
12  nm.  NPSH levels were expressed as mmol  NPSH/g tis-
ue.
.7.2.  Ascorbic acid (AA) determination
AA determination was performed as described by
acques-Silva et al. [32]. Proteins were precipitated in
0  volumes of a cold 4% trichloroacetic acid solution.
n aliquot of the sample at a ﬁnal volume of 1 ml  of
he  solution was incubated at 38 ◦C for 3 h then 1 ml
2SO4 65% (v/v) was added to the medium. The reac-
ion product was determined using a colour reagent
ontaining 4.5 mg/ml  dinitrophenyl hydrazine and CuSO4
0.075 mg/ml) at 520 nm.  The content of ascorbic acid is
elated  to tissue amount (mol  ascorbic acid/g wet tis-
ue)..8. Protein determination
Protein  concentration was measured by the method of
radford  [33], using bovine serum albumin as the standard.
ig. 2. Effect of Triton WR-1339 (T), simvastatin (S) and chrysin (Cr) on plasma lipi
HDL)-cholesterol, (c) non-HDL-cholesterol, and (d) triglyceride levels from plasm
er  group. *Compared to control group (C); #compared to Triton WR-1339 group (T
o  simvastatin + Triton (S + T) (P < 0.05 – Student’s t test).ports 1 (2014) 200–208 203
2.9.  Statistical analysis
Statistical  analysis of data was  performed using a
two-way analysis (Chrysin × Triton WR-1339 and simvas-
tatin  × Triton WR-1339) of variance (ANOVA), followed by
post  hoc comparisons using Newman Keuls test when
appropriate. Main effects are presented only when the
second order interaction was not signiﬁcant. To compare
treatments, chrysin and simvastatin, the Student t test
was  applied. Experiments were expressed as mean ± S.D.
Differences between groups were considered statistically
signiﬁcant when P < 0.05.
3.  Results
3.1. Plasma lipids
Two-way  ANOVA of total cholesterol levels data
yielded a signiﬁcant Triton WR-1339 × chrysin interaction.
Post hoc comparison demonstrated that Triton WR-1339
increased plasmatic total cholesterol levels in mice. Chrysin
pretreatment was effective in preventing the increase of
total  cholesterol levels caused by Triton WR-1339 injection
in  mice. Two-way ANOVA of cholesterol total data yielded a
signiﬁcant  Triton WR-1339 × simvastatin interaction. Sim-
vastatin  pretreatment was  effective in partial preventing
the increase of cholesterol total levels caused by Triton WR-
1339  injection in mice. T-test demonstrated that there is no
signiﬁcant  difference between simvastatin and Triton WR
1339  × chrysin and Triton WR-1339 groups (Fig. 2a).
d levels in C57BL/6 mice. (a) total cholesterol, (b) high-density lipoprotein
a of C57BL/6 mice. Data are reported as mean ± S.D. for ﬁve to six animals
) (P < 0.05-two-way analysis of variance/Newman Keuls) and @compared
ology Reports 1 (2014) 200–208
Fig. 3. Effect of Triton WR-1339 (T), simvastatin (S) and chrysin (Cr) on
markers of oxidative stress from liver of C57BL/6 mice, TBARS content
from liver of C57BL/6 mice. Data are reported as mean ± S.D. for ﬁve to
not  able in protect the decrease on catalase activity caused
by  Triton WR-1339 injection in mice. T-test demonstrated
that there is no signiﬁcant difference P > 0.05 between
Fig. 4. Effect of Triton WR-1339 (T), simvastatin (S) and chrysin (Cr) on204 M.S. Zarzecki et al. / Toxic
Two-way ANOVA of HDL-cholesterol levels showed a
signiﬁcant Triton WR-1339 main effect. Post hoc com-
parison demonstrated that Triton WR-1339 decreased
plasmatic HDL-cholesterol levels in mice. Pretreament
with chrysin and simvastatin did not protect the decrease
on  HDL-cholesterol levels caused by Triton WR-1339 injec-
tion  in mice. Two-way ANOVA of HDL-cholesterol levels
showed a signiﬁcant Triton WR-1339 main effect. T-test
demonstrated that there is no signiﬁcant difference P > 0.05
between  simvastatin and Triton WR-1339 × chrysin and
Triton  WR-1339 groups (Fig. 2b).
Two-way ANOVA of non-HDL-cholesterol levels yielded
a  signiﬁcant Triton WR-1339 × chrysin interaction. Post
hoc  comparison demonstrated that Triton WR-1339
increased plasma non-HDL-cholesterol levels in mice.
Chrysin pretreatment partially decreased non-HDL-
cholesterol levels caused by Triton WR-1339 injection
in mice. Two-way ANOVA of non-HDL-cholesterol lev-
els  showed a signiﬁcant Triton WR-1339 × simvastatin
interaction. Simvastatin pretreatment partially decreased
non-HDL-cholesterol levels caused by Triton WR-1339
injection in mice. T-test demonstrated that there isn’t
signiﬁcant difference (P > 0.05) between simvastatin and
Triton  WR-1339 × chrysin and Triton WR-1339 groups
(Fig. 2c).
Two-way ANOVA of triglyceride data revealed a sig-
niﬁcant Triton WR-1339 × chrysin interaction. Post hoc
comparison demonstrated that Triton WR-1339 increased
the  plasma triglycerides levels in mice. Oral administra-
tion of chrysin in mice partially blocked the increase of
triglyceride levels induced by Triton WR-1339 injection
in  mice. Two-way ANOVA of triglyceride data revealed
a  signiﬁcant Triton WR-1339 × simvastatin interaction.
Simvastatin pretreatment partially decreased triglyceride
levels caused by Triton WR-1339 injection in mice. T-test
demonstrated that there is a signiﬁcant different (P < 0.05)
between  simvastatin and Triton WR-1339 × chrysin and
Triton  WR-1339 groups (Fig. 2d).
3.2. Oxidative stress markers
Two-way  ANOVA of TBARS data revealed a signiﬁcant
Triton WR-1339 × Chrysin interaction. Post hoc compari-
son  demonstrated that Triton WR-1339 increased TBARS
levels  in mice. Oral administration of chrysin signiﬁcantly
prevented the increase of TBARS levels induced by Triton
WR-1339 injection in mice. Two-way ANOVA of TBARS
data  revealed a signiﬁcant Triton WR-1339 × simvastatin
interaction. Simvastatin pretreatment decreased TBARS
levels  caused by Triton WR-1339 injection in mice. T-test
demonstrated that there is no signiﬁcant difference P > 0.05
between  simvastatin and Triton WR-1339 × chrysin and
Triton  WR-1339 groups (Fig. 3).
Chrysin pretreatment per se decreased carbonyl levels
in  mice compared with group control. However, there was
no  change in carbonyl protein in any of the other groups.3.3.  Enzymatic antioxidant defenses
Two-way ANOVA of SOD data revealed signiﬁcant Tri-
ton  WR-1339 × chrysin interaction. Post hoc comparisonsix  animals per group. *Compared to control group (C); #compared to Tri-
ton  WR-1339 group (T) (P < 0.05-two-way analysis of variance/Newman
Keuls).
demonstrated that Triton WR-1339 decreased SOD lev-
els  in mice. Oral administration of chrysin signiﬁcantly
prevented the decrease of SOD levels induced by Triton
WR-1339 injection in mice. Simvastatin pretreatment did
not  protect the decrease on SOD levels caused by Tri-
ton  WR-1339 injection in mice. T-test demonstrated that
there  is signiﬁcant difference P < 0.05 between simvastatin
and Triton WR-1339 × chrysin and Triton WR-1339 groups
(Fig.  4)
Two-way ANOVA of catalase activity showed a signif-
icant Triton WR-1339 main effect. Post hoc comparison
demonstrated that Triton WR-1339 decreased catalase
activity in mice. Chrysin and simvastatin pretreatment wasantioxidant enzyme defense, superoxide dismutase from liver of C57BL/6
mice. Data are reported as mean ± S.D. for ﬁve to six animals per group.
*Compared to control group (C); #compared to Triton WR-1339 group (T)
(P  < 0.05-two-way analysis of variance/Newman Keuls) and @compared to
simvastatin + Triton (S + T) (P < 0.05 – Student’s t test).
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imvastatin and Triton WR-1339 × chrysin and Triton WR-
339  groups.
.4.  Non enzymatic antioxidant defenses
NPSH and ascorbic acid data showed that chrysin,
imvastatin and Triton WR-1339 did not change these
arameters in livers of mice.
. Discussion
The purpose of this study was to demonstrate the
ypolipidemic action of chrysin on Triton WR-1339-
nduced hyperlipidemia in female C57BL/6 mice. A single
ral  dose (10 mg/kg) of chysin was able to prevent the
ncrease of total cholesterol levels, partially prevent the
ncrease  on non-HDL-cholesterol and triglyceride lev-
ls,  but it was not able to prevent the decrease on
DL-cholesterol levels induced by Triton WR 1339 admin-
stration in this experimental protocol. Additionally, we
bserved  the ability of chrysin in act on parameters of
xidative stress, protecting the alteration on lipid perox-
dation levels and SOD activity induced by Triton WR  1339
n  mice.
In  our study, we observed the increase in the lev-
ls of total cholesterol (3.0-times higher than the control
roup), non-HDL-cholesterol (5.3-times higher than the
ontrol  group) and triglycerides (12.5-times higher than
he  control group) and decrease on HDL-cholesterol levels
2.5-times lower than the control group) 24 h after a single
riton  WR-1339 injection in mice. The results demon-
trated here were in accordance with those reported by
thers  [11,25]. Several studies have shown that systemic
dministration of Triton WR-1339 (nonionic surfactant)
n  fasted rats and mice causes increased level of lipids in
lasma  [25]. Initially there is a sharp increase in lipid level
eaching a peak in two to three times the control value
4  h after the injection of Triton WR-1339 phase I (syn-
hesis phase), this falls within hyperlipidemia next 24 h or
8  h after administration of Triton WR-1339, Phase II (the
limination phase) [26].
The  nonionic detergent, Triton WR-1339, has been used
idely  to block the uptake of triacylglycerol-rich lipo-
roteins from plasma by peripheral tissues to produce
cute hyperlipidemia in animal models, which are often
sed  for a number of objectives, in particular for screening
atural or chemical hypolipidemic drugs [11,34]. Experi-
ental evidence supports the concept that Triton WR-1339
hysically alters very low density lipoproteins (VLDL), ren-
ering  them refractive to the action of lipolytic enzymes
f  blood and tissue [35]. This prevents or delays their
emoval from blood and secondarily stimulates the hepatic
holesterol biosynthesis, enhancing the hyperlipidemia
36]. There was marked increase in the level of serum
otal cholesterol, triglycerides, phospholipids, LDL, VLDL
nd  decrease in the level of cholesterol carrier HDL in the
ats  treated with Triton WR-1339 [26].It was observed that chrysin, given by the oral route
o C57BL/6 female mice at a simple dose of 10 mg/kg,
resented a hypolipidemic effect by preventing the aug-
entation of total cholesterol, and partly prevents theports 1 (2014) 200–208 205
increase  in non-HDL-cholesterol and triglyceride levels in
a  Triton WR-1339-induced hyperlipidemic model. These
results  are of great importance since the ﬂavonoids like
chrysin are viewed as important components of ‘func-
tional foods’, acting as modiﬁers of cardiovascular disease
[37].  Chrysin has effects cardioprotective against myocar-
dial  ischaemia/reperfusion injury in Langendorff-perfused
rat hearts [38]. Furthermore, some patients under statin
treatment cannot tolerate statins well or do not reach the
low-density lipoprotein-cholesterol (LDL-C) goal recom-
mended by the US National Institutes of Health guidelines
[39]. Therefore, it is desirable to develop natural drugs that
have  cholesterol-lowering effect comparable to statins, but
could  be tolerated well by the patients.
In addition, the results presented here were signiﬁcant
since it is the ﬁrst study using female mice of line C57BL/6
that receiving treatment with chrysin in this model of
hyperlipidemia. We  chose female because it has more risk
for  cardiovascular disease. Schwab et al. [40] showed dif-
ferences  in the distribution of cardiovascular risk factors
in  disfavour of females, including higher cholesterol lev-
els.  In study of Kautzky-Willer et al. [41], women  showed
higher mean total cholesterol levels than men, and overall,
women tended to feature hyperlipidemia more often than
their  male counterparts. In the obese and hypertonic sub-
groups,  LDL cholesterol was also higher in the women than
in  the men.
Other studies involving anti-hyperlipidemic proﬁle of
chrysin  have been performed in rats. Pushpavalli et al.
[15]  demonstrated that treatment with chrysin, at dose of
25  mg/kg in rats, was effective in decreased total choles-
terol, triglycerides, free fatty acids, LDL-cholesterol and
VLDL  cholesterol and increased HDL cholesterol levels in
a  model d-galactosamine-induced hepatotoxicity. More-
over,  higher doses (50 mg/kg and 100 mg/kg) of chrysin
have resulted in the production of by-products, interfer-
ing  with the hepatoprotective activity, and consequently,
decreasing its effect [15]. In the study of Anandhi et al. [42]
chrysin  at the dose of 200 mg/kg protected against hyper-
cholesterolemia induced by Triton WR-1339 in rats. In our
study  a single dose of 10 mg/kg body weight was  able to
protect  an increase in plasma lipid levels, showing that
even  at a dose 10 times lower, chrysin has managed to have
a  positive effect against hyperlipidemia in this protocol
model. Unlike previous studies, we demonstrated here the
preventive  effect of chrysin, at lower dose, against hyper-
lipidemia and encourage its consumption in the diet as a
preventive agent for cardiovascular diseases.
An important point of this work is that chrysin had
better effect than simvastatin in reducing plasma lipid
levels, mainly triglycerides. A possible explanation for
the  hypolipidemic action of chrysin is related to HMG-
CoA  reductase activity, mechanism similar than statins,
another hypotheses are related to lipoprotein lipase activ-
ity,  responsible to decrease plasma triglycerides levels.
However, more studies are needed to identify the mech-
anisms of chrysin in this hyperlipidemia model. Therefore,
our  results suggest that chrysin supplementation can be
used  as an adjuvant on treatment of dyslipidemia.
Knowing that chrysin has antioxidant effect and that
an  important property of a compound that may affect
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 potentiFig. 5. Scheme with
hyperlipidemia is its antioxidant capacity we investigated
whether Triton WR-1339-induced acute hyperlipidemia in
female  C57BL/6 mice altered some parameters of oxidative
damage in the hepatic tissue and whether the antioxidant
effect of chrysin was related to this process.
In our study Triton WR-1339 administered to mice was
able  to increase the marker of stress oxidative TBARS and
decrease the activity antioxidant by enzyme SOD. Stokes
et  al. [43] reported that ROS levels in hypercholesterolemia
were higher than in the normal state. In agreement with
this,  Oh et al. [7], found that 18 h after Triton WR-1339
administration to mice, the level of plasma TBARS was
increased and the activity of two hepatic detoxicating
enzymes, catalase and GPx, were decreased compared with
the  control group. Thus, in this study the hepatic markers
of  oxidative stress were altered in mice treated with Triton
WR-1339. Oxygen free radicals or, more generally, reactive
oxygen  species (ROS), are the products of normal metabolic
and  signal-transduction events within a cell but free radical
oxidation is responsible for the degradation of fatty acids
and  their esters in biological membranes and lipoproteins
[44], consequently, this oxidation may  also play a role in
pathologic processes.
Chysin  prevented the alteration on oxidative stress
markers, it signiﬁcantly decreased TBARS level of plasma
and  prevented the decrease on enzymatic antioxidant
defenses SOD changed by Triton WR-1339. These results
demonstrated the antioxidant action of chrysin in this
model and suggest this effect as a possible mechanism of
chrysin  hypolipidemic action. Rice-Evans [45], described
the  beneﬁcial effects of chrysin by having the capabil-
ity of free radicals scavenging. Ciftci et al. [24], showed
that chrysin (50 mg  kg, per oral route) signiﬁcantly increaseal targets of chrysin.
GSH,  CAT, GSH-Px and CuZn-SOD levels, but did not change
the  formation of TBARS in rat tissues. Sirovina et al. [46],
demonstrated that administration of quercetin and chrysin
to  diabetic mice resulted in a signiﬁcant decrease in lipid
peroxidation level in liver tissue.
5. Conclusions
In conclusion, our ﬁndings demonstrated that chrysin
(dose of 10 mg/kg), has antihyperlipidemic effect since it
was  able to prevent the augmentation of plasma total
cholesterol, non-HDL cholesterol and triglyceride levels
in  the plasma of Triton WR-1339-induced hyperlipidemia
in mice. Furthermore antihyperlipidemic action of chrysin
demonstrated in this study was  comparable to the standard
drug  simvastatin. The antioxidant effect of chrysin in liver
was  observed in this experimental protocol and it was  sug-
gested  as a possible mechanism of chrysin hypolipidemic
action (Fig. 5). Thus, our results suggest that chrysin supple-
mentation can be used as an adjuvant on treatment of
dyslipidemia diseases, since dyslipidemia is a major risk
factor  for coronary heart disease in women.
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